We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Calcium Phosphate and Incretins

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01296997
Recruitment Status : Completed
First Posted : February 16, 2011
Last Update Posted : November 7, 2012
Sponsor:
Information provided by (Responsible Party):
Gerhard Jahreis, University of Jena

Brief Summary:
The study was conducted to investigate the effect of a calcium phosphate supplementation on the secretion of incretins.

Condition or disease Intervention/treatment
Healthy Men Dietary Supplement: calcium phosphate Other: placebo

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Influence of a Calcium Phosphate Supplementation on the Secretion of Incretins in Humans.
Study Start Date : July 2010
Primary Completion Date : September 2010
Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium
U.S. FDA Resources

Arm Intervention/treatment
Experimental: calcium phosphate Dietary Supplement: calcium phosphate
the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
Placebo Comparator: placebo Other: placebo
the subjects consumed a bread without pentacalcium phosphate



Primary Outcome Measures :
  1. secretion of incretins [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. concentration of minerals in plasma [ Time Frame: 3 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy men

Exclusion Criteria:

  • intake of dietary supplements and chronic diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01296997


Locations
Germany
Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology
Jena, Thuringia, Germany, 07743
Sponsors and Collaborators
University of Jena
Investigators
Principal Investigator: Gerhard Jahreis, Prof. Dr. Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gerhard Jahreis, Prof. Dr. habil, University of Jena
ClinicalTrials.gov Identifier: NCT01296997     History of Changes
Other Study ID Numbers: LSEP H45-10
First Posted: February 16, 2011    Key Record Dates
Last Update Posted: November 7, 2012
Last Verified: November 2012

Keywords provided by Gerhard Jahreis, University of Jena:
calcium phosphate
incretins
human study

Additional relevant MeSH terms:
Calcium, Dietary
Incretins
Bone Density Conservation Agents
Physiological Effects of Drugs
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists